Article
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Science (New York, N.Y.) - 4 Jun 2004
Paez J Guillermo, Jänne Pasi A, Lee Jeffrey C, Tracy Sean, Greulich Heidi, Gabriel Stacey, Herman Paula, Kaye Frederic J, Lindeman Neal, Boggon Titus J, Naoki Katsuhiko, Sasaki Hidefumi, Fujii Yoshitaka, Eck Michael J, Sellers William R, Johnson Bruce E, Meyerson Matthew
Abstract excerpt
Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15of 58 unselected tumors from Japan and 1 of 61 from the United States. Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan. EGFR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
